Advisory, Initial Public Offering and Pharmaceutical

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Advisory

Initial Public Offering

Pharmaceutical

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Cooley’s 2023 Activism Year in Review: Wolfpacks at the Gate

Cooley M&A

JANUARY 30, 2024

7] Winning the support of the proxy advisory firms (ISS and Glass Lewis) continued to be crucial, particularly for the activists: Of the nine activist proxy contest victories, only two came without the support of at least one of the proxy advisory firms. (On

Private Equity

Private Equity M&A Investors Capital

Investment Banking Today

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley’s 2023 Activism Year in Review: Wolfpacks at the Gate

Stay Connected